Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)

Abdallah G. Rebeiz, Jean Pierre Dery, Anastasios A. Tsiatis, J. Conor O'Shea, Brent A. Johnson, Anne S. Hellkamp, Karen S. Pieper, Ian Gilchrist, James Slater, J. Brent Muhlestein, Diane Joseph, Michael M. Kitt, James E. Tcheng

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.

Original languageEnglish (US)
Pages (from-to)926-929
Number of pages4
JournalAmerican Journal of Cardiology
Issue number7
StatePublished - Oct 1 2004

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)'. Together they form a unique fingerprint.

Cite this